SC
Shivali Choudhary
About Shivali Choudhary
Shivali Choudhary has 8 years in corporate governance. Holds Director role. Currently with 2 companies, including Zymes Bioscience Private Limited and Zalix Pharmaceuticals Private Limited. Formerly with 2 companies, such as Astrom Bioscience Private Limited and Biomak Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Zymes Bioscience Private Limited
U51102DL2012PTC234105
|
Director | 25 May 2022 | 2012 | Active |
Zalix Pharmaceuticals Private Limited
U74993DL2018PTC333678
|
Director | 09 May 2018 | 2018 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Astrom Bioscience Private Limited
U51397DL2012PTC231902
|
Director | 19 Apr 2019 | 2012 | Active |
Biomak Laboratories Private Limited
U24230HR2021PTC098857
|
Director | 07 Aug 2023 | 2021 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Shivali Choudhary
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shivali Choudhary
Shivali Choudhary has 8 years in corporate governance. Holds Director role. Currently with 2 companies, including Zymes Bioscience Private Limited and Zalix Pharmaceuticals Private Limited. Formerly with 2 companies, such as Astrom Bioscience Private Limited and Biomak Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations.
Shivali Choudhary is associated with 2 companies as Director.
Shivali Choudhary has expertise in General Business.
Shivali Choudhary has 8 years in corporate governance.